Parabilis Medicines (PBLS) FDA Approvals $22.75 -2.43 (-9.65%) As of 10/16/2026 04:00 PM Eastern Add Compare Share Share FDA Events Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsInsider TradesNews and TrendsOwnershipSEC FilingsShort Interest Parabilis Medicines' Drug in the FDA Approval ProcessThis section highlights FDA-related milestones and regulatory updates for drugs developed by Parabilis Medicines (PBLS). Over the past two years, Parabilis Medicines has reported clinical trial outcomes, regulatory submissions, approvals, and other FDA events for drugs and therapies such as Zolucatetide. For definitions of regulatory abbreviations such as NDA, BLA, or PDUFA, see the event status legend. Zolucatetide FDA Regulatory Events Zolucatetide is a drug developed by Parabilis Medicines for the following indication: key driver of a range of cancers and tumor types. This drug is under review by the U.S. Food and Drug Administration (FDA). Below is a timeline of key regulatory milestones for this therapy. Provided Update - October 14,2026Provided Update Phase 1/2Drug: ZolucatetideAnnounced Date: October 14, 2026Indication: key driver of a range of cancers and tumor types.AnnouncementParabilis Medicines announced the initiation of a dose-ranging clinical cohort evaluating zolucatetide in patients with familial adenomatous polyposis (FAP) as part of the company’s ongoing Phase 1/2 clinical trial. Zolucatetide is Parabilis’ lead investigational Helicon™ peptide and the first and only direct inhibitor of the β-catenin:TCF interaction, a key driver of a range of cancers and tumor types.Read Announcement Parabilis Medicines FDA Events - Frequently Asked Questions Has Parabilis Medicines received FDA approval? As of now, Parabilis Medicines (PBLS) has not received any FDA approvals for its therapy in the last two years. What drugs has Parabilis Medicines submitted to the FDA? In the past two years, Parabilis Medicines (PBLS) has reported FDA regulatory activity for Zolucatetide. What is the most recent FDA event for Parabilis Medicines? The most recent FDA-related event for Parabilis Medicines occurred on October 14, 2026, involving Zolucatetide. The update was categorized as "Provided Update," with the company reporting: "Parabilis Medicines announced the initiation of a dose-ranging clinical cohort evaluating zolucatetide in patients with familial adenomatous polyposis (FAP) as part of the company’s ongoing Phase 1/2 clinical trial. Zolucatetide is Parabilis’ lead investigational Helicon™ peptide and the first and only direct inhibitor of the β-catenin:TCF interaction, a key driver of a range of cancers and tumor types." What conditions do Parabilis Medicines' current drugs treat? Currently, Parabilis Medicines has one therapy (Zolucatetide) targeting the following condition: key driver of a range of cancers and tumor types.. More FDA Event Resources from MarketBeat FDA Calendars Recent FDA Drug Approval Calendar Upcoming FDA Events & PDUFA Dates Calendar Companies With Recent FDA Events Ascendis Pharma A/S FDA EventsIonis Pharmaceuticals FDA EventsOmeros FDA EventsRegeneron Pharmaceuticals FDA EventsSanofi FDA EventsTiziana Life Sciences FDA EventsTango Therapeutics FDA EventsOrganon & Co. FDA EventsAquestive Therapeutics FDA EventsCrescent Biopharma FDA EventsCellectar Biosciences FDA EventsEdesa Biotech FDA EventsEupraxia Pharmaceuticals FDA EventsImmunocore FDA EventsInsmed FDA Events FDA Event Stage Terminology & Abbreviation Guide NDA: New Drug Application ANDA: Abbreviated New Drug Application sNDA: Supplemental New Drug Application BLA: Biologics License Application sBLA: Supplemental Biologics License Application FDA Approved: Approved by the FDA EMA: European Medicines Agency CE Mark: European Union Certification NMPA: China National Medical Products Administration MHLW: Japanese Ministry of Health FDA Meeting: Consultation with FDA Pre-IND: Pre-Investigational New Drug Meeting Breakthrough Therapy: Special FDA designation for promising therapies Fast Track: Accelerated FDA approval pathway Orphan Drug: Designation for rare disease treatments RPD: Rare Pediatric Disease Designation RMAT: Regenerative Medicine Advanced Therapy DSMB Review: Data Safety Monitoring Board Review IDMC Review: Independent Data Monitoring Committee MAA: MHRA Marketing Authorization Application RTF: Refusal to File (Rejected Application) 510(k): FDA Clearance for Medical Devices Rolling Submission: Staggered regulatory review process Related Companies BridgeBio Pharma FDA Events Halozyme Therapeutics FDA Events Madrigal Pharmaceuticals FDA Events BioMarin Pharmaceutical FDA Events Vaxcyte FDA Events Krystal Biotech FDA Events Protagonist Therapeutics FDA Events Kymera Therapeutics FDA Events Arrowhead Pharmaceuticals FDA Events TG Therapeutics FDA Events Stock Lists Biotechnology StocksCompare Biotech StocksCompare Healthcare StocksCompare Pharmaceutical StocksHealthcare Stocks FDA progress for NASDAQ:PBLS last updated on 10/14/2026 by MarketBeat.com Staff. We continuously monitor for new FDA events and market data. From Our PartnersElon Musk’s 4th Wealth Window Set to Open by October 30Jeff Brown, the analyst who flagged Bitcoin, Tesla, and Nvidia early, is tracking Elon Musk's next move. He po...Brownstone Research | SponsoredFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leadin...Weiss Ratings | SponsoredThis link won't stay freeThe 0DTE Game Plan normally sells for 29.97, but it is free today through this link. Inside is a straightfo...Profits Run | SponsoredINSANE DRONE FOOTAGENew drone footage shows a mysterious factory rising at one of Elon Musk's most secure facilities, cleared and ...Paradigm Press | SponsoredA weekly dividend fund holding Nvidia and PalantirCrowdStrike, Palantir, Nvidia none of them pay a real dividend. But one fund holding the biggest AI names dist...Investors Alley | SponsoredThe Claude AI company doubled in value... you missed itIn May, Anthropic raised money at a $965 billion valuation. Now, ahead of its IPO, investors are reportedly di...Crypto 101 Media | SponsoredI'm giving you a space stock today. Free.On December 8th, $600 billion in frozen SpaceX stock comes loose. Dylan Jovine says one simple purchase in any...Behind the Markets | SponsoredWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one t...Awesomely | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Parabilis Medicines, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Parabilis Medicines With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Provided Update - October 14,2026Provided Update Phase 1/2Drug: ZolucatetideAnnounced Date: October 14, 2026Indication: key driver of a range of cancers and tumor types.AnnouncementParabilis Medicines announced the initiation of a dose-ranging clinical cohort evaluating zolucatetide in patients with familial adenomatous polyposis (FAP) as part of the company’s ongoing Phase 1/2 clinical trial. Zolucatetide is Parabilis’ lead investigational Helicon™ peptide and the first and only direct inhibitor of the β-catenin:TCF interaction, a key driver of a range of cancers and tumor types.Read Announcement
Free PBLS Stock Alerts